【AI详解】The dawn of mRNA vaccines: The COVID-19 case.

文献信息

一句话小结

本文回顾了COVID-19疫情期间两种获批的mRNA疫苗BNT162b2和mRNA-1273的快速发展及其科学基础，探讨了mRNA疫苗的设计、组成和临床表现，以及SARS-CoV-2作为研究案例的意义。研究表明，理解这些疫苗的免疫原性和反应原性特征对未来mRNA疫苗的优化和开发至关重要。

在麦伴科研 (maltsci.com) 搜索更多文献

mRNA疫苗 · COVID-19 · SARS-CoV-2 · 免疫原性 · 反应原性

摘要

在COVID-19疫情爆发不到一年的时间里，两种基于mRNA的疫苗BNT162b2和mRNA-1273获得了首次历史性的紧急使用授权，而另一种mRNA疫苗CVnCoV也进入了第三阶段临床测试。COVID-19 mRNA疫苗代表了一类新的疫苗产品，这些疫苗由合成的mRNA链构成，编码SARS-CoV-2的刺突糖蛋白，并以脂质纳米颗粒的形式包装，以便将mRNA递送到细胞中。本文回顾了过去几十年中的科学突破，这些突破为COVID-19疫情期间mRNA疫苗的快速发展奠定了基础。除了为mRNA疫苗提供动力外，SARS-CoV-2还成为一个理想的案例研究，使我们能够比较不同mRNA疫苗候选者之间的设计-活性差异。因此，本文详细概述了三种最先进的mRNA疫苗的组成及其（前）临床表现，并深入讨论了它们的结构设计选择对免疫原性和反应原性特征的影响。除了强调mRNA疫苗作用机制的新基础见解外，我们还指出了仍需进一步研究的未知因素，以及未来mRNA疫苗开发中可能需要优化的方面。

英文摘要

In less than one year since the outbreak of the COVID-19 pandemic, two mRNA-based vaccines, BNT162b2 and mRNA-1273, were granted the first historic authorization for emergency use, while another mRNA vaccine, CVnCoV, progressed to phase 3 clinical testing. The COVID-19 mRNA vaccines represent a new class of vaccine products, which consist of synthetic mRNA strands encoding the SARS-CoV-2 Spike glycoprotein, packaged in lipid nanoparticles to deliver mRNA to cells. This review digs deeper into the scientific breakthroughs of the last decades that laid the foundations for the rapid rise of mRNA vaccines during the COVID-19 pandemic. As well as providing momentum for mRNA vaccines, SARS-CoV-2 represents an ideal case study allowing to compare design-activity differences between the different mRNA vaccine candidates. Therefore, a detailed overview of the composition and (pre)clinical performance of the three most advanced mRNA vaccines is provided and the influence of choices in their structural design on to their immunogenicity and reactogenicity profile is discussed in depth. In addition to the new fundamental insights in the mRNA vaccines’ mode of action highlighted here, we also point out which unknowns remain that require further investigation and possibly, optimization in future mRNA vaccine development.

麦伴智能科研服务

主要研究问题

1. mRNA疫苗在其他传染病的应用前景如何？
2. 与传统疫苗相比，mRNA疫苗的免疫反应机制有哪些显著差异？
3. 未来mRNA疫苗开发中存在哪些技术挑战和未知数？
4. 不同mRNA疫苗的结构设计对其安全性和有效性的影响是什么？
5. 如何评估mRNA疫苗在变异病毒株中的有效性和适应性？

核心洞察

研究主题和范围

本综述探讨了新冠疫情期间mRNA疫苗的迅速发展，重点分析了三种主要mRNA疫苗（BNT162b2、mRNA-1273和CVnCoV）的科学突破、结构设计及其对免疫原性和反应性的影响。文章还讨论了mRNA疫苗的作用机制及未来研究方向。

主要发现和观点

1. mRNA疫苗的崛起：COVID-19疫情推动了mRNA疫苗的快速发展，首次获得FDA和EMA的紧急使用授权，标志着疫苗研发的革命性进展。
2. 科学基础：过去几十年的研究为mRNA疫苗的成功奠定了基础，尤其是对先天免疫机制的理解以及脂质纳米颗粒（LNP）在mRNA传递中的关键作用。
3. 疫苗比较：BNT162b2和mRNA-1273采用修饰的mRNA，而CVnCoV则使用未修饰的mRNA，三者在抗原选择、LNP设计和mRNA结构上存在差异。

研究进展

• 疫苗设计：所有mRNA疫苗都靶向SARS-CoV-2的刺突蛋白，采用不同的结构优化策略来提高稳定性和翻译效率。
• 免疫反应：mRNA疫苗主要诱导B细胞产生中和抗体，同时也激活CD4+和CD8+ T细胞，提供广泛的免疫保护。
• 临床试验结果：BNT162b2和mRNA-1273的有效性分别为95%和94.1%，并在实际应用中表现出极高的保护效果。

争议与不足

• 反应性：未修饰mRNA疫苗（如CVnCoV）显示出更高的反应性，可能与其引发的强烈先天免疫反应有关。
• 长期免疫：疫苗诱导的免疫反应的持续时间和对新变种的保护能力仍需进一步研究。

未来研究方向

1. 优化疫苗设计：未来的研究应聚焦于mRNA的结构设计及其对免疫反应的影响，以提高疫苗的安全性和有效性。
2. 长期跟踪研究：需要开展长期随访研究，以评估疫苗诱导的免疫持久性及对新变种的保护能力。
3. 扩展应用：mRNA技术的成功可能促进其在其他传染病和肿瘤免疫治疗中的应用。

通过对mRNA疫苗的深入分析，本文强调了其在公共卫生危机中的重要性及未来发展潜力，预示着mRNA技术可能在疫苗研发领域开启新的篇章。

参考文献

1. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. - Kizzmekia S Corbett;Barbara Flynn;Kathryn E Foulds;Joseph R Francica;Seyhan Boyoglu-Barnum;Anne P Werner;Britta Flach;Sarah O’Connell;Kevin W Bock;Mahnaz Minai;Bianca M Nagata;Hanne Andersen;David R Martinez;Amy T Noe;Naomi Douek;Mitzi M Donaldson;Nadesh N Nji;Gabriela S Alvarado;Darin K Edwards;Dillon R Flebbe;Evan Lamb;Nicole A Doria-Rose;Bob C Lin;Mark K Louder;Sijy O’Dell;Stephen D Schmidt;Emily Phung;Lauren A Chang;Christina Yap;John-Paul M Todd;Laurent Pessaint;Alex Van Ry;Shanai Browne;Jack Greenhouse;Tammy Putman-Taylor;Amanda Strasbaugh;Tracey-Ann Campbell;Anthony Cook;Alan Dodson;Katelyn Steingrebe;Wei Shi;Yi Zhang;Olubukola M Abiona;Lingshu Wang;Amarendra Pegu;Eun Sung Yang;Kwanyee Leung;Tongqing Zhou;I-Ting Teng;Alicia Widge;Ingelise Gordon;Laura Novik;Rebecca A Gillespie;Rebecca J Loomis;Juan I Moliva;Guillaume Stewart-Jones;Sunny Himansu;Wing-Pui Kong;Martha C Nason;Kaitlyn M Morabito;Tracy J Ruckwardt;Julie E Ledgerwood;Martin R Gaudinski;Peter D Kwong;John R Mascola;Andrea Carfi;Mark G Lewis;Ralph S Baric;Adrian McDermott;Ian N Moore;Nancy J Sullivan;Mario Roederer;Robert A Seder;Barney S Graham - The New England journal of medicine (2020)
2. The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration. - Lien Van Hoecke;Kenny Roose;Marlies Ballegeer;Zifu Zhong;Niek N Sanders;Stefaan De Koker;Xavier Saelens;Sandra Van Lint - Molecular therapy. Nucleic acids (2020)
3. Virus-specific memory CD8 T cells provide substantial protection from lethal severe acute respiratory syndrome coronavirus infection. - Rudragouda Channappanavar;Craig Fett;Jincun Zhao;David K Meyerholz;Stanley Perlman - Journal of virology (2014)
4. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don’t. - R L Juliano - Nucleic acid therapeutics (2018)
5. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. - Tom T Shimabukuro;Matthew Cole;John R Su - JAMA (2021)
6. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. - Ugur Sahin;Petra Oehm;Evelyna Derhovanessian;Robert A Jabulowsky;Mathias Vormehr;Maike Gold;Daniel Maurus;Doreen Schwarck-Kokarakis;Andreas N Kuhn;Tana Omokoko;Lena M Kranz;Mustafa Diken;Sebastian Kreiter;Heinrich Haas;Sebastian Attig;Richard Rae;Katarina Cuk;Alexandra Kemmer-Brück;Andrea Breitkreuz;Claudia Tolliver;Janina Caspar;Juliane Quinkhardt;Lisa Hebich;Malte Stein;Alexander Hohberger;Isabel Vogler;Inga Liebig;Stephanie Renken;Julian Sikorski;Melanie Leierer;Verena Müller;Heidrun Mitzel-Rink;Matthias Miederer;Christoph Huber;Stephan Grabbe;Jochen Utikal;Andreas Pinter;Roland Kaufmann;Jessica C Hassel;Carmen Loquai;Özlem Türeci - Nature (2020)
7. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. - Akin Akinc;William Querbes;Soma De;June Qin;Maria Frank-Kamenetsky;K Narayanannair Jayaprakash;Muthusamy Jayaraman;Kallanthottathil G Rajeev;William L Cantley;J Robert Dorkin;James S Butler;Liuliang Qin;Timothy Racie;Andrew Sprague;Eugenio Fava;Anja Zeigerer;Michael J Hope;Marino Zerial;Dinah W Y Sah;Kevin Fitzgerald;Mark A Tracy;Muthiah Manoharan;Victor Koteliansky;Antonin de Fougerolles;Martin A Maier - Molecular therapy : the journal of the American Society of Gene Therapy (2010)
8. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. - Daniel Wrapp;Nianshuang Wang;Kizzmekia S Corbett;Jory A Goldsmith;Ching-Lin Hsieh;Olubukola Abiona;Barney S Graham;Jason S McLellan - Science (New York, N.Y.) (2020)
9. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. - Katalin Karikó;Michael Buckstein;Houping Ni;Drew Weissman - Immunity (2005)
10. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. - Nina Le Bert;Anthony T Tan;Kamini Kunasegaran;Christine Y L Tham;Morteza Hafezi;Adeline Chia;Melissa Hui Yen Chng;Meiyin Lin;Nicole Tan;Martin Linster;Wan Ni Chia;Mark I-Cheng Chen;Lin-Fa Wang;Eng Eong Ooi;Shirin Kalimuddin;Paul Anantharajah Tambyah;Jenny Guek-Hong Low;Yee-Joo Tan;Antonio Bertoletti - Nature (2020)

引用本文的文献

1. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. - Linde Schoenmaker;Dominik Witzigmann;Jayesh A Kulkarni;Rein Verbeke;Gideon Kersten;Wim Jiskoot;Daan J A Crommelin - International journal of pharmaceutics (2021)
2. Lack of Informations about COVID-19 Vaccine: From Implications to Intervention for Supporting Public Health Communications in COVID-19 Pandemic. - Silva Guljaš;Zvonimir Bosnić;Tamer Salha;Monika Berecki;Zdravka Krivdić Dupan;Stjepan Rudan;Ljiljana Majnarić Trtica - International journal of environmental research and public health (2021)
3. Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles. - Christophe Delehedde;Luc Even;Patrick Midoux;Chantal Pichon;Federico Perche - Pharmaceutics (2021)
4. Metal-Organic Frameworks-Based Nanomaterials for Drug Delivery. - Mohammad Reza Saeb;Navid Rabiee;Masoud Mozafari;Ebrahim Mostafavi - Materials (Basel, Switzerland) (2021)
5. The dynamics of quantitative SARS-CoV-2 antispike IgG response to BNT162b2 vaccination. - Shun Kaneko;Masayuki Kurosaki;Toru Sugiyama;Yuka Takahashi;Yoshimi Yamaguchi;Masayuki Nagasawa;Namiki Izumi - Journal of medical virology (2021)
6. Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across. - An-Katrien Minnaert;Helena Vanluchene;Rein Verbeke;Ine Lentacker;Stefaan C De Smedt;Koen Raemdonck;Niek N Sanders;Katrien Remaut - Advanced drug delivery reviews (2021)
7. Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2. - Javier T Granados-Riveron;Guillermo Aquino-Jarquin - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2021)
8. Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasms. - Douglas B Snider;Greer K Arthur;Guido H Falduto;Ana Olivera;Lauren C Ehrhardt-Humbert;Emmaline Smith;Cierra Smith;Dean D Metcalfe;Glenn Cruse - Molecular therapy : the journal of the American Society of Gene Therapy (2022)
9. Pre-Drawn Syringes of Comirnaty for an Efficient COVID-19 Mass Vaccination: Demonstration of Stability. - Francesca Selmin;Umberto M Musazzi;Silvia Franzè;Edoardo Scarpa;Loris Rizzello;Patrizia Procacci;Paola Minghetti - Pharmaceutics (2021)
10. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. - Franz X Heinz;Karin Stiasny - NPJ vaccines (2021)

… (211 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研